Lepirudin: is the approved dosing schedule too high?

被引：20

作者：

Hacquard, M

De Maistre, E

Lecompte, T

机构：

[1] Henri Poincare Univ, INSERM, U734, Nancy, France

[2] Univ Hosp Nancy, Haematol Lab, Nancy, France

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2005年 / 3卷 / 11期

关键词：

D O I：

10.1111/j.1538-7836.2005.01620.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2593 / 2596

页数：4

共 9 条

[1]

*ANAES, 2002, REC PRAT CLIN DIAGN, P78

[2]

Eichler P, 2000, BLOOD, V96, P2373

[3]

Glusa E, 1998, KIDNEY INT, pS54

[4]

GREINACHER A, 2004, HEPARIN INDUCED THRO, P397

[5] Hirudin determination in plasma can be strongly influenced by the prothrombin level [J].

Lindhoff-Last, E ;

Piechottka, GP ;

Rabe, F ;

Bauersachs, R .

THROMBOSIS RESEARCH, 2000, 100 (01) :55-60

[6] Decreasing adverse drug events associated with lepirudin and argatroban for the treatment of heparin-induced thrombocytopenia [J].

McDaniel, M ;

Soff, GA .

BLOOD, 2004, 104 (11) :495A-495A

[7] Monitoring of recombinant hirudin: Assessment of a plasma-based ecarin clotting time assay [J].

Potzsch, B ;

Hund, S ;

Madlener, K ;

Unkrig, C ;

MullerBerghaus, G .

THROMBOSIS RESEARCH, 1997, 86 (05) :373-383

[8] Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin [J].

Song, XH ;

Huhle, G ;

Wang, LC ;

Hoffmann, U ;

Harenberg, J .

CIRCULATION, 1999, 100 (14) :1528-1532

[9] Heparin-induced thrombocytopenia: Recognition, treatment, and prevention [J].

Warkentin, TE ;

Greinacher, A .

CHEST, 2004, 126 (03) :311S-337S

← 1 →